Drug intelligence / Profile preview

NB-73

Development stage: Preclinical
Modality: Small Molecules

Overview

NB-73 is a small molecule inhibitor that targets the Forkhead box protein M1 (FOXM1) transcription factor. It is a potent, selective, and efficacious inhibitor of FOXM1 in high-grade serous ovarian cancer (HGSOC) cells, suppressing FOXM1 target genes, inducing apoptotic cell death, and synergizing with standard chemotherapy (carboplatin). NB-73 displays superior potency, efficacy, and selectivity compared to other known FOXM1 inhibitors, and is under investigation as a potential therapeutic agent for HGSOC.

Other names: FOXM1 inhibitor NB-73FOXM-1 inhibitor NB-73FOXM 1 inhibitor NB-73

Targets

FOXM1 (Forkhead box protein M1)

Beyond the preview

Go deeper on NB-73.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB-73.

Explore the full profile